Late treatment study
et al., medRxiv, doi:10.1101/2020.09.16.20194571 (Preprint) (meta analysis - not included in study count)
Mortality outcomes with hydroxych loroquine and ch loroquine in COVID-19: an international collaborative meta-analysis of randomized trials
Meta analysis assigning 87% weight to the RECOVERY trial, producing the same result. The RECOVERY trial used excessively high non-patient-customized dosage in very sick late stage patients and the result is not generalizable to typical dosage or earlier treatment.
Please send us corrections, updates, or comments.